Warfarin is a widely used anticoagulant that is critical in reducing patient morbidity and mortality associated with thromboembolic disorders. However, its narrow therapeutic index and large inter-individual variability can lead to complex dosage regimes. Formulating warfarin as an orodispersible film (ODF) using thermal ink-jet (TIJ) printing could enable personalisation of therapy to simplify administration. Commercial TIJ printers are currently unsuitable for printing the milligram dosages, typically required for warfarin therapy. As such, this study aimed to modify a commercial TIJ printing system to formulate personalised warfarin ODFs containing therapeutic dosages. A TIJ printer was modified successfully with the printer functionality intact; the substrate (paper) rolling mechanism of the printer was replaced by printing onto a stationary stage. Free film substrates were composed of hydroxypropyl methylcellulose (20%w/w) and glycerol (3%w/w). The resulting ODFs were characterised for morphology, disintegration, solid-state properties and drug content. Printed film stability was assessed at 40°C/75% relative humidity for 30 days. Therapeutic warfarin doses (1.25 and 2.5 mg) were successfully printed onto the film substrates. Excellent linearity was observed between the theoretical and measured dose by changing the warfarin feed concentration (R 2 = 0.9999) and length of the print objective, i.e. the Yvalue, (R 2 = 0.9998). Rapid disintegration of the ODFs was achieved. As such, this study successfully formulated personalised warfarin ODFs using a modified TIJ printer, widening the range of applications for TIJ printing to formulate narrow therapeutic index drugs.
Introduction
Warfarin is the primary drug of choice for long-term anticoagulation in a variety of conditions, including venous thrombosis, pulmonary embolism and atrial fibrillation (Reynolds et al., 2007; BNF, 2017) . However, its narrow therapeutic index and large inter-individual variability create a number of challenges (Kimmel, 2008) . Warfarin dosages must be individualised for each patient to ensure that the anticoagulant effect is safe and effective, typically reflected in an International Normalised Ratio (INR) range of 2-3 (Crowther et al., 1999) . Critically, inadequate control of INR can lead to severe adverse effects; under-anticoagulation can predispose patients to thrombosis, whereas over-anticoagulation can increase the risk of bleeding (Kimmel, 2008) .
Despite the importance of maintaining warfarin within the therapeutic range, around 50% of patients fail to achieve their target INR (Matchar et al., 2002) . Warfarin has also been listed in the top three most likely drugs to cause adverse reactions leading to hospital admissions (Pirmohamed et al., 2004) . This could be partly explained by warfarin's inherently complex dosage regime and monitoring requirements. Therapeutic doses for different patients can vary widely, requiring anywhere between 4.5 and 77.25 mg per week (Wang and Hsaio, 2012; Wadelius et al., 2003) . However, commercially available warfarin tablets are manufactured in only a few fixed strengths (0.5 mg, 1 mg, 3 mg and 5 mg) (BNF, 2017) . As such, patients are often required to take a combination of strengths, split tablets or take different dosages on alternate days. This increases the risk of patient confusion, medication errors and non-adherence, potentially leading to severe adverse effects or therapeutic failure (Kimmel, 2008; Wong et al., 1999) .
Personalised medicine has been suggested as a solution to ensure the safe and effective use of narrow therapeutic index drugs (Mini and Nobili, 2009; Alomari et al., 2015) . In the case of warfarin, tailored dosing has been estimated to prevent 85,000 serious bleeding events and save $1.1 billion each year within the United States alone (McWilliam et al., 2006) . As such, there is a major clinical need for the development of warfarin as a formulation that permits dose flexibility and personalisation.
Advances in personalised medicines demand precise, rapid and flexible manufacturing platforms capable of printing customised dosage forms directly at the point of care. Inkjet printing, a form of 2-Dimensional (2D) printing, has received increasing attention within pharmaceuticals. The general process involves dissolving or suspending an active pharmaceutical ingredient into a liquid carrier in order to create an "ink". The small 'ink' droplets (2-180 pL) are then ejected from a nozzle onto a solid substrate using either thermal (TIJ) or piezoelectric ink-jets. Both techniques have previously been used to deposit active pharmaceutical ingredients onto edible substrates (Uddin et al., 2015; Lee et al., 2012; Meléndez et al., 2008; Buanz et al., 2011; Vakili et al., 2017) . A thermal inkjet printer was utilised for this work.
In brief, a TIJ system is comprised of a print head on a cartridge which serves as a reservoir for the 'ink'. A current is pulsed through a resistive element in the print head, causing an internal temperature rise and subsequent vaporisation, nucleation and expansion of a bubble, which imparts sufficient energy to eject a droplet. The droplet is then precisely deposited onto a solid substrate; this has enabled inkjet printing to find numerous pharmaceutical applications. To date, this technology has been used to coat and load drug-eluting stents (Tarcha et al., 2007) , to coat transdermal microneedles (Uddin et al., 2015) and to manufacture drug-loaded microparticles (Lee et al., 2012; Palmer et al., 2017) .
In the context of personalised medicines, TIJ could be used to print a variety of individualised dosages onto an edible substrate, such as orodispersible films (ODFs). This concept was demonstrated by Buanz. et al., whereby a highly potent drug (salbutamol sulphate; 40 μg/cm 2 per print pass) was printed onto an edible potato starch film (Buanz et al., 2011) . However, commercially available TIJ printers are only able to deposit very low doses (approximately a maximum of 35 μg/ print cycle). As such, this technology is currently only suitable for formulating highly potent drugs (Alhnan et al., 2016) .
This provides a challenge when attempting to formulate narrow therapeutic index drugs that typically require dosing within the milligram range, such as warfarin. Researchers have attempted to increase drug deposition via a number of approaches, for example by using multiple printing cycles ) and higher feed concentrations (Raijada et al., 2013) . However, challenges surrounding non-linearity of drug deposition and crystallisation of active pharmaceutical ingredient were found. To extend the applications of TIJ, it is clear that a novel method to increase the amount of drug deposition is required.
As such, this study describes the modification of a commercial TIJ printing system to formulate customised warfarin ODFs (up to milligram dosages). The resulting ODFs were characterised and evaluated for drug content and stability.
Materials and Methods

Materials
Sodium warfarin was obtained from LKT Labs, UK; hydroxypropyl methylcellulose (HPMC) 6cp, i.e., Pharmacoat ® 606 was obtained from Shin-Etsu, Japan; glycerol was from VWR chemicals, UK; and the fluoropolymer coated polyester film, Scotch pack release liner 1022, was from 3 M Inc., US. Fast Green dye was purchased from Alfa Aesar, UK. The water used in all experiments was ultrapure water.
Printer Modification and Evaluating Robustness
A Hewlett-Packard printer (HP 5940 Deskjet, USA, Fig. 1 ) was used in this work. This printer was modified such that rather than the substrate (generally paper in the unmodified printer) passing through the printer's rollers during operation, printing was done onto a stage mounted underneath the cartridge print head. Briefly, the modification process involved the careful removal of some physical parts of the printer to make room for fixing a stationary stage under the cartridge print head as shown in Fig. 1 . Key sensors were also identified, carefully isolated so as not to damage these, and manually activated appropriately to ensure normal printer functioning.
In the unmodified printer, two key sensors require activation for the printing process to take place: the printer lid sensor and the paper feed sensor. During a normal printing process, the lid sensor is engaged with a bar attached to the printer lid and the paper feed sensor is activated by disengaging a bar which is required for paper to be fed into the printer.
In the modified printer, the printer lid is removed and printing is performed onto a stationary substrate without a paper rolling mechanism. These activations are manually performed by placing a bar between the lid sensor to mimic a closed printer lid; a requirement for printing functionality. The paper feed sensor is also manually activated by removing a bar which is placed between the sensors when the printer is idle.
HP 337 black cartridges were used in this work: these were modified by cutting off the top, draining the ink, and rinsing several times with deionised water until clear. The cartridge nozzles were then submerged in deionised water: ethanol solution (2:1) for 5 min.
An experiment to evaluate any potential inter-or intra-cartridge variations due to the modification was conducted. Three modified HP 337 black cartridges were used for this experiment. 1 mg/mL Fast Green dye solution was used as the "ink" for printing. 1 cm × 1 cm squares were printed in triplicate for each cartridge onto the clear acetate sheets. The print-outs were then carefully cut and immersed in 1 mL deionised water to dissolve the dye. The dye solutions were vortexed to ensure complete dissolution after which high-performance liquid chromatography (HPLC) analysis was conducted.
The liquid chromatographic system used was Agilent Technologies 1200 series with quaternary pump and degasser. The column used was a Phenomenex C 18 column (150 mm × 3.90 mm, 5 μm). A gradient system was adopted with acetonitrile HPLC grade as the organic phase and 55 mM acetate buffer (pH 5 ± 0.02) as the aqueous phase at a flow rate of 1 mL/min for 10 min. The gradient system consisted of 15% acetonitrile and 85% buffer for 6 min then 60% acetonitrile and 40% buffer for a minute after which 15% acetonitrile and 85% buffer run again for 3 min. An injection volume 10 μL was used with the column temperature set at 30°C. A wavelength of 600 nm was used for detection.
Film Preparation
The placebo film gel was composed of HPMC and glycerol. Glycerol (3% w/w) was first dissolved in water at room temperature, followed by gradual addition of HPMC (20%w/w) under continuous stirring at room temperature. The resulting viscous solution (10 g) was stirred for 4 h until a homogenous gel was formed. The gel was left to stand for 2 h to eliminate any air bubbles trapped.
Placebo films were casted on a fluoropolymer coated polyester sheet using an automated film applicator (Coatmaster 510, Erichsen, Sweden) equipped with an adjustable coating blade. A fixed wet film thickness (1000 μm) and casting speed (5 mm/s) were used. The casted films were dried in an oven for 40 min at 60°C (Binder, Sweden), followed by storage in a desiccator (23°C/40% relative humidity). The resulting film sheets were used as substrates for printing.
Printing of Warfarin onto Films
Amounts of warfarin deposited onto a substrate can generally be varied by using different cartridge concentrations or by modifying the dimensions of the templates to be printed. In modifying the dimensions of the templates, a series of rectangles having the same width but variations in their height were deposited onto the same unit area. This resulted in an increase in the amount of material deposited and the concept is referred to as "Y-value". An example of the Y-value concept is illustrated in Fig. 2 , where three black rectangles have the same width (0.5 cm) but Y-value (length of the print objective) changed from 0.5 cm to 1.5 cm in this scenario. Printing these templates onto a fixed area results in a linear increment in the volume of solution deposited. A variety of warfarin doses were printed on substrates, customised by changing the Y-value (1-7 cm). The printed films were dried at ambient conditions. Aqueous solutions of warfarin of varying concentrations (10, 40, 80, 160 and 300 mg/mL) were also printed using 1 cm × 1 cm templates.
Spray Drying
300 mg warfarin and 900 mg HPMC were dissolved in 50 mL of water. The resultant aqueous solution was spray dried using a Buchi 190 Spray dryer (Switzerland) in an open configuration with air as the drying gas. The processing conditions were: air flow 357 L h −1 , aspiration rate 100% and solution feed rate 5 mL min −1
. The inlet temperature was fixed at 130°C for water. The outlet temperatures were in the range of 50-55°C.
Characterization of Films
Drug Content Analysis
Films were dissolved in water under stirring for 1 h (1 cm 2 in 50 mL). Solutions were filtered through a 0.45 μm filter (Millex syringedriven filter unit, Millipor Ltd., Ireland). The filtrate was analysed using the HPLC method described in Section 2.2 and detection performed at a wavelength of 214 nm.
Film Thickness and Disintegration
The thickness of the films (1cm 2 ) was measured using a digital micrometer (Cokraft®, Digital caliper, Sweden) at three points of each sample, and reported as mean ± SD. The disintegration time of the films was then evaluated by a modified Petri dish method (Garsuch and Breitkreutz, 2010) . Samples (1 × 1 cm 2 ) were placed in a Petri dish containing 2 mL of water and shaken at 60 rpm using arbitral shaker water bath at 37 ± 1°C. The time until film disintegration or disruption was recorded.
Contact Angle
The contact angle of the warfarin droplets on the placebo substrates (1 × 4 cm) was measured using the DSA100 drop shape analyser (KRÜSS GmbH, Hamburg, Germany). The contact angle was measured immediately after the drop was deposited onto the substrate. The behaviour of the printing solution on the substrate was captured using the video camera within the DSA100.
Viscosity of the Warfarin ink Solution
The viscosity of the warfarin ink solution range of 10-300 mg/mL was measured using an Anton Paar rolling ball microviscometer (Anton Paar, Graz, Austria). Samples were transferred to a glass viscometry capillary (1.6 mm diameter) containing a steel ball. Viscosity was determined as the time taken for the ball to fall 25 cm through the sample at an angle of 50, 60 and 70°to the horizontal; each automated, timed determination was performed four times. The measurements were performed at 25°C.
Solid State Properties
Thermal analyses were performed using differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). DSC was performed using a differential scanning calorimeter (DSC Q1000, TA Instruments, USA) and each sample (> 5 mg) was placed in a hermetically-sealed aluminium pan with a pinhole lid. The following heatcool-heat cycles were performed with a nitrogen purge gas (50 mL/ min): 1. The sample was heated from 25°C to 100°C at 10°C/min (to remove water content). 2. The sample was cooled from 100°C to 0°C without ramp. 3. The sample was re-heated from 0°C to 200°C at 10°C/ min above the melting temperature of warfarin. An empty pan was used as a reference and the instrument was previously calibrated for temperature and heat capacities using indium and sapphire. DSC results were analysed using Universal Analysis software (TA instruments, USA). TGA measurements were performed using a TGA instrument (TA instruments, USA). Approximately 5-8 mg of the film was heated from 25 to 150°C at 10°C/min using nitrogen as a purge gas (50 mL/min). Data collection and analysis were performed using Universal Analysis software (TA instruments, USA).
Attenuated Total Reflection-Fourier Transform Infrared Spectroscopy (ATR-FTIR)
Attenuated Total Reflection-Fourier Transform Infrared Spectroscopy (ATR-FTIR) was performed with a Perkin-Elmer Spectrum 100 FTIR Spectrometer using the universal diamond ATR attachment. P.R. Vuddanda et al. European Journal of Pharmaceutical Sciences 117 (2018) 80-87 The spectra were collected in the range of 4000-650 cm −1 at ambient conditions using a minimum number of four scans per sample. Spectra were analysed with Spectrum Express software.
Surface Morphology
Surface and cross-section morphology of films were captured with an FEI Inspect F50 Scanning Electron Microscope (SEM) (FEI, Hillsboro, OR, USA). Film cross-sections were immersed in liquid nitrogen; through a fracture by freezing method, clean-cut edges were ensured and plastic deformation avoided. These were then fixed on aluminium stubs by conductive carbon tape, and sputter-coated with gold (approx. 10-12 nm) in a high vacuum evaporator (108 Auto, Cressington Scientific Instruments Ltd., UK).
Polarised light microscopy (PLM) was performed using a Nikon microphoto-FXA light microscope to collect optical images with an Infinity 2 digital camera and capture application software (version 3.7.5).
Film Stability
To evaluate the film stability, samples of warfarin-printed films were packed in polyethylene-sealed pouches and stored in a glass desiccator (40°C/75% relative humidity) for 30 days. Drug recrystallisation, moisture content, surface morphology, drug content and disintegration time were examined on day 30.
Statistical Analysis
Student t-test for two group comparisons and one-way ANOVA with Tukey's post hoc multiple comparisons were used to determine statistically significant differences (p-value < 0.05).
Results and Discussion
The thermal ink-jet printer used in this work was the HewlettPackard (HP) 5940 Deskjet. The printer was modified such that rather than the substrate (paper in the unmodified printer) passing through the printer's rollers during operation, printing was done onto a stage mounted underneath the cartridge print head without the printer detecting the absence of paper. The key point with the printer modification is to identify the printer's sensors and manually activate these when needed.
The modifications to the printer mean that when printing an image, the substrate does not move vertically. Changing the volume of solution being deposited is achieved simply by changing the dimensions of the rectangular template used to initiate printing. The width of the rectangle is kept fixed and the height varied for the series of rectangles. Since the height is conventionally the y-axis, we denote this term as the 'Y-value'; with each y-value corresponding to the height of the rectangle in cm.
The modified printer maintained its functionality and an evaluation of its robustness was conducted using the relative standard deviation (RSD) values. RSD values of 2.17%, 0.25%, and 0.87% were obtained for the three cartridges (Table 1) . These low values (< 5% RSD) indicated the repeatability and precision of the printing procedure, highlighting the robust nature of the modified inkjet.
Using a modified TIJ printer platform, a variety of warfarin doses were successfully deposited onto film substrates. The amount of drug deposited was altered using two main methods; by changing the feed concentration and the Y-values.
Firstly, the concentration of warfarin within the initial feed solution was varied (10, 40, 80, 160 and 300 mg/mL) using a 1 cm 2 template. In this case, an excellent linear correlation was found between the feed solution concentration and warfarin dose deposition (R 2 = 0.9999) (Fig. 3) . Furthermore, highly precise and accurate doses of warfarin were deposited. These results indicate that the printing mechanism of TIJ (which involves rapid localised heating) was not affecting drug stability neither did the printer modification affect droplet reproducibility. One challenge of using concentrated feed solutions is that there is a risk of drug crystallisation on the nozzle tip (and nozzle blockage), especially if the drug is at or above saturated conditions (Raijada et al., 2013) . Within this study, feedstock concentrations above the reported aqueous solubility of warfarin of 0.017 mg/ml were used (PubChem, Warfarin, 2018) . As such, the printing process was closely monitored to ensure that recrystallization did not occur or affect droplet placement and accuracy. Another consideration is liquid viscosity (Alomari et al., 2015) . The viscosity of the different ink solutions of warfarin (10-300 mg/mL) were between 1.10 and 1.31 mPa·S, which are in line Table 1 The area under curve for modified cartridges and the relative standard deviations for printed templates using fast green dye (n = 3).
Cartridge
Average area under curve Fig. 3 . Amount of warfarin (μg/mL) printed onto free film substrates upon varying the feed solution concentrations (mg/mL) using a 1cm 2 template (n = 3). 43 ± 2 47 ± 1 Disintegration time free film (sec) 42 ± 2 -P.R. Vuddanda et al. European Journal of Pharmaceutical Sciences 117 (2018) 80-87 with the literature of thermal inkjet printing solutions (16). Secondly, the Y-values (with a width of 1 cm) were varied (1-7 cm) whilst maintaining a constant warfarin feed concentration (300 mg/ mL). The time taken for printing of the highest length (7 cm) was 23 ± 1 s. The correlation between Y-values and dose deposited also demonstrated good linearity, high precision and accuracy (R 2 = 0.9998) (Fig. 4) . At a feed concentration of 300 mg/mL and a Yvalue of 7 cm, warfarin doses of 2.5 mg/cm 2 were successfully printed.
However, it was observed that surface erosion and deformation of the substrate occurred at Y-values above 7 cm. This was likely due to the films being composed of a water-soluble polymer (HPMC) that may have dissolved in the aqueous environment, causing film instability and breakdown. Encouragingly, the modified TIJ printer deposited therapeutic dosages of warfarin (2.5 mg/cm 2 using a 300 mg/mL cartridge concentration) onto substrates. This means that the physical dimensions of printed films (2 × 1 cm) contained warfarin doses equivalent to widely prescribed therapeutic doses (5 mg). Commercial TIJ printers are only able to deposit very low doses, making this technology currently only suitable for high potency drugs. For example, Buanz. et al. could print 40 μg of salbutamol sulphate onto an ODF platform (Buanz et al., 2011; Sandler et al., 2011) . In this current study, by increasing the print objective Y-value, a higher amount of warfarin solution, and hence dose, was deposited. This extends the applications of TIJ printing towards formulating narrow therapeutic index drugs. Printed films containing a 2.5 mg/cm 2 dose of warfarin were found to have a thickness of 72 ± 2 μm). No significant differences were observed when compared to the free film substrate thickness (70 ± 1 μm). Disintegration time is considered one of the most important characteristics for the performance of ODFs. Typical disintegration times for ODFs range from 5 s to 30 s. However, there is no official method to determine disintegration of ODFs, which makes a comparison between various publications difficult. There have been many attempts at modelling in vivo conditions to evaluate ODF disintegration, such as the Petri dish method and the slide frame method (Irfan et al., 2016) . Within this study, a modified Petri dish method was used to assess disintegration time.
In general, disintegration/dissolution of ODFs is dependent on surface tension, wettability, porosity, thickness, disintegration media and molecular interactions (Miller-Chou and Koenig, 2003; Vuddanda et al., 2017) . Vuddanda. et al. observed significant differences in the disintegration time of ondansetron ODFs that possessed different microstructures (Vuddanda et al., 2016) . Furthermore, Preis. et al. reported different disintegration times for films prepared with different combinations of polymers (Preis et al., 2014) . In this study, warfarin-printed films containing different doses (1.25 and 2.5 mg) and the free film substrate all disintegrated within 45 s (Table 2) . These results also indicate that disintegration was not significantly affected by the presence of warfarin. The printed film disintegration times are in agreement with ODFs composed of HPMC reported in literature (Liew et al., 2012) .
To determine the surface interaction between the feed solution and film substrates, the contact angle of the warfarin printing solution (300 mg/mL) was measured. Following immediate deposition on the substrate, the contact angle was 38.18 ± 1°. The deposited droplet rapidly penetrated the surface of the substrate, suggesting the warfarin was absorbed into the substrate matrix. Neither surface erosion nor dissolution of the substrate was visually observed at the printing site during contact angle analysis. DSC thermograms of samples are shown in Fig. 5 . A broad endothermic peak at T onset (ΔH f ) = 190.6°C was observed in the DSC thermogram of pure warfarin and physical mixture (1:3), indicating that warfarin was in the crystalline state and could be detected by DSC. Interestingly, for the TIJ printed films, no melting peak was observed, indicating that warfarin was present in the amorphous phase (Gao and Maurin, 2001 ). This may be due to HPMC inhibiting the crystal growth in solid dispersions by preventing molecular mobility due to its complex polymer network (Ozaki et al., 2013; Tajarobi et al., 2011) .
To further explore this, a solid dispersion of warfarin and HPMC (1:3) was prepared by spray drying. The drug content was equivalent to that of the printed films containing 2.5 mg/cm 2 . DSC has been found to be an appropriate technique to determine drug solubility within a polymer (Haddadin et al., 2009) . The characteristic warfarin recrystallisation peak was not observed in the thermogram of the spray dried solid dispersion (Fig. 5) , confirming that warfarin was present in the amorphous state within the HPMC polymer substrate.
Water content was analysed based on the weight loss of films using TGA. The weight loss of the warfarin-HPMC spray-dried product was 0.40%, confirming water removal during the spray drying process. For film substrates and freshly printed films, the observed weight losses were 0.86% and 1.14%, respectively (Fig. 6 ). In the case of printed films kept under accelerated storage conditions for 30 days (40°C/75% relative humidity), weight losses were higher at 3.05%. This was likely due to the higher moisture content within the storage environment.
The ATR-FTIR spectra for warfarin (pure), spray dried warfarin-HPMC and TIJ printed warfarin films (freshly printed and stability) are shown in Fig. 7 . ATR-FTIR spectrum of pure warfarin showed the following characteristic sharp intense bands; the stretching of lactone C] O bond is observed at 1681 cm and 1681 cm −1 were completely diluted or showed a lower intensity in the spray dried and printed samples. These shifts in spectral bands could be attributed to the amorphisation of warfarin and/or possible intermolecular hydrogen bonding between warfarin and HPMC. Significant spectral shifts were not observed in the case of stability tested samples compared to freshly printed films. The surface morphologies of both the free film substrate and warfarin printed films were observed using SEM (Fig. 8) . Fig. 8a shows the free film substrate, which exhibited an irregular and porous microstructure compared to the freshly printed film, which showed a parallel and uniform droplet-printing pattern (Fig. 8b) . The cross-sectional SEM images qualitatively showed the homogenous microstructure of the HPMC polymer matrix substrate. Typical drug printing impressions can be observed on top of the substrate for printed warfarin films.
Polarised light microscopy (PLM) images of substrates and printed films were in agreement with SEM images Fig. 9 . Neither drug crystallisation nor surface deformation was observed. Buanz. et al. reported similar PLM images of clonidine printed films (Buanz et al., 2015) . Fig. 7 . ATR-FTIR spectra of a) warfarin (pure), b) Spray dried warfarin-HPMC product (1:3 ratio), c) Freshly printed warfarin film and d) warfarin printed films after 30 days' storage. Fig. 8 . SEM images of a) HPMC free film substrate, b) Freshly printed warfarin films and c) warfarin printed films after 30 days' storage. Surface micrographs (top) and cross sections (bottom) of each sample set. P.R. Vuddanda et al. European Journal of Pharmaceutical Sciences 117 (2018) 80-87 Warfarin printed films were stored at 40°C/75% relative humidity for 30 days. Drug content and disintegration time were not affected upon storage compared to freshly printed warfarin films (Table 2) . Furthermore, drug recrystallisation or erosion of films was not observed in SEM images (surface and cross-section) or PLM images. This was supported by the absence of a characteristic warfarin melting point peak (~187°C) in the endotherm of printed film, confirming warfarin was present in the amorphous phase. This may be due to warfarin being dispersed at a molecular level or adequately solubilised within the HPMC substrate. However, marked changes (buckling with partial crumbling) on the surface microstructure occurred on storage ( Fig. 8 and Fig. 9 ). As such, to be used clinically, moisture absorption preventative packaging might be required to retain the film's physical appearance for patient acceptance.
Conclusion
Personalisation of warfarin therapy is critical to ensure patient safety and maintain therapeutic effect. This study successfully formulated warfarin ODFs in a range of therapeutic dosages (1.25 mg and 2.5 mg) using a modified TIJ printer. Doses were varied by changing the feed concentration and the length of the print objective (Y-value). In both cases, a linear relationship between the theoretical and measured warfarin dose was achieved, demonstrating a highly robust and accurate process. Compared to commercial TIJ printers, the modified system enabled a higher dose deposition, widening the range of applications to include formulating narrow therapeutic index drugs. This paper demonstrates the potential for TIJ printing to personalise warfarin therapy, reducing the risk of adverse effects and therapeutic failure.
